



Food Standards Australia New Zealand  
PO Box 5423  
KINGSTON ACT 2604  
AUSTRALIA

15 December 2023

**RE: Submission – A1273 - Steviol glycosides as a food additive in Food for special medical purposes [270-23], 17 November 2023**

Ingredion is a global ingredient solutions company manufacturing sweeteners, starches, and unique ingredients from plant sources such as corn, tapioca, rice, sago, and potato. The business is focused on providing critical ingredients to the food, beverage, industrial, pharmaceutical, and personal care industries.

Ingredion has a global network of manufacturing facilities, Ingredion Idea Labs™ innovation centers and sales offices with over 11,000 employees. The business is headquartered in Westchester, Illinois USA.

**Overall Comments**

Ingredion has reviewed the Call for submissions document including the supporting risk and technical assessment material.

Ingredion notes a reason for the requested amendment is to align the Code with international permissions, including the European Union (EU), and with provisions listed in the *Codex Alimentarius* (Codex) standard.

Ingredion notes the draft variation to the Code proposed by FSANZ results in permissions for steviol glycosides to be used as a food additive in FSMP including very low energy foods produced for consumption as part of a VLED and all other FSMP which are not aligned with international permissions such as Codex General Standard for Food Additives (GSFA).

**Specific Comments**

Ingredion **supports** permission for the food additive, steviol glycosides, for use in the manufacture of Food for Special Medical Purposes (FSMP).

Ingredion **supports** the proposed the maximum permitted level (MPL) of the food additive of 330 mg/kg (as steviol equivalents) in very low energy foods produced for consumption as part of a very low energy diet (VLED).



Ingredion notes the proposed the maximum permitted level (MPL) of the food additive of 75mg/kg (as steviol equivalents) for all other FSMP. This level is significantly lower than international permissions and will no doubt result in issues for imported products and limit the availability of such FSMPs to Australia & New Zealand consumers for dietary management of specific medical conditions.

Thank you for the opportunity to provide input to the Call for Submissions for A1273.

If you require any further information, please do not hesitate to contact me.

Sincerely,

